On June 28 the U.S. Food and Drug Administration (FDA) approved Gilead Sciences Epclusa, a new once-daily combination pill containing sofosbuvir and velpatasvir, for the treatment of adults with hepatitis C virus (HCV) genotypes 1 through 6 -- the first approved oral pangenotypic regimen. While it is more effective against more types of HCV, Epclusa will cost less than most earlier interferon-free direct-acting antiviral regimens.
More than 49,000 people in the U.S. have filled prescriptions for Truvada for pre-exposure prophylaxis (PrEP) at retail pharmacies, according to the results of a survey by Gilead Sciences presented this week at the ASM Microbe conference in Boston. Among PrEP users with available data, most were white gay men; black people used PrEP much less often, despite having the highest rates of HIV infection.
In April, coinciding with the International Liver Congress in Barcelona, the World Health Organization (WHO) released an update to its Guidelines for the Screening, Care and Treatment of Patients with Chronic Hepatitis C Infection. The guidelines promote the transition to newer, more effective direct-acting antiviral (DAA) medications that have the potential to cure most people living with hepatitis C. Also during the meeting the European Association for the Study of the Liver (EASL) announced it would update its hepatitis C treatment guidelines at a special conference in September.
HIVandHepatitis.com coverage of the 2016 European Association for the Study of the Liver International Liver Congress (EASL 2016) in Barcelona, April 13-17, 2016.
Conference highlights include interferon-free hepatitis C treatment for people with advanced disease, experimental HCV therapy, new treatment for hepatitis B, and management of liver disease complications.